On 11 May, Dutch parliament will decide whether to fast track the introduction of the “Wet Homologatie Onderhands Akkoord’, known as ‘WHOA’ or the Dutch Scheme. The legislation would lead to a major improvement of financial restructuring possibilities in the Netherlands for domestic and international companies outside of a formal insolvency procedure.
If successful, the proposed scheme will be introduced by 1 July 2020 combining features from the U.K. Scheme of Arrangements and US Chapter 11 proceedings, while also providing a flexible procedure and limited court involvement.
Based on A&M’s experience, most companies in trouble are not only overleveraged but may also have other operational issues. These issues need to be addressed as part of a parallel operational restructuring process next to a WHOA procedure. For this reason, A&M sees the WHOA procedure as part of a full restructuring process.
Click here to download our insights document.
La conformité comme levier de valorisation transactionnelle
January 27, 2026
Dans un contexte où les données et les actifs technologiques deviennent des moteurs clés de valorisation, la conformité ne se limite plus au respect des règles. Elle conditionne désormais la transférabilité, l’exploitabilité et in fine la valeur réelle des actifs lors d’opérations de carve-out, de joint-venture ou de M&A.
Valuation Insights in Spain 2025
January 27, 2026
We are pleased to share the December 2025 edition of Valuation Insights in Spain, a detailed analysis of key market trends and developments shaping valuation practices in Spain and Europe. This report explores topics such as EV/EBITDA multiples in M&A transactions, industry performance comparisons across the S&P Europe 350 Index, and shifts in equity investment risks.
Navigating Global Pharma Policy
January 26, 2026
As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could be felt across the global healthcare landscape. For an industry already grappling with rising R&D costs and competitive pressures, these tariffs threaten to erode profit margins and disrupt finely tuned supply chains.
The State of Transformation for U.S. Healthcare Providers
January 26, 2026
Market dynamics for health systems are shifting. The most significant driver is the federal Medicaid mandate, which expired at the end of December 2025 and is now pending legislation. This uncertainty is prompting health system leaders to rethink strategy and operations. In this context, we’ll share how other health systems are responding and what these changes mean for organizations like yours.
